October 14, 2013
Study demonstrates addition of recombinant human platelet-derived growth factor lead to significantly more vital bone formation at four to five months following sinus augmentation.
Researchers from the New York College of Dentistry (NYUCD) and Bluestone Center for Clinical Research have published, “A Histomorphometric Comparison of Bio-Oss Alone Versus Bio-Oss and Platelet-Derived Growth Factor for Sinus Augmentation: A Postsurgical Assessment,” (http://1.usa.gov/1akVYUU) in the International Journal of Periodontics and Restorative Dentistry.
The article was co-authored by Ismael Khouly, DDS, MS, clinical assistant professor of oral and maxillofacial surgery and clinical research coordinator at the Bluestone Center for Clinical Research and Stuart J. Froum, DDS, clinical professor and director of clinical research in the Ashman Department of Periodontology and Implant Dentistry, NYUCD. Other authors include Stephen Wallace, DDS, Sang-Choo Cho, DDS, Edwin Rosenberg, DMD, Scott Froum, DDS, Robert Schoor, DDS, Patrick Mascarenhas, DDS, Dennis Tarnow, DDS, Nicolas Elian, DDS, Stefan Fickl, DDS, John Ricci, PhD, Bin Hu, MD, Timothy Bromage, PhD, and Patricia Corby, DDS, MS, Associate Director, Bluestone Center for Clinical Research.
Sinus augmentation is often performed to increase the amount of bone in the posterior upper jaw prior to the placement of an implant. Ever since the introduction of this procedure, researchers have been evaluating bone graft materials best suited for implant placement. Initially, bone graft material was harvested from the same patient using an oral or extra-oral donor site (autogenous bone). However, to minimize patient discomfort, increase patient acceptability, and decrease morbidity associated with donor sites, the focus of research shifted towards other materials. A multitude of graft materials have been utilized and studied. The ideal graft material should provide a high percentage of vital bone after a reasonable healing period, equal or better than autogenous bone. The use of bone replacement graft materials like Bio-Oss in sinus augmentation has become more common, and can be an effective alternative to harvesting autogenous bone. Bio-Oss is an anorganic bovine bone matrix (ABBM) that is a safe, effective bone substitute for intraoral grafting procedures.
Furthermore, advances in biomaterial research have obtained excellent outcomes. Growth factors, such as platelet-derived growth factor (PDGF), are wound healing hormones produced naturally at sites of soft tissue and bone healing. PDGF in particular has been shown to promote wound healing in both soft and hard tissues and has been found to be safe and effective in clinical trials for over 10 years. The goal of the prospective, blinded, randomized study was to assess the efficacy of ABBM with and without recombinant human PDGF (rhPDGF) in producing vital bone at four to five months and seven to nine months following sinus augmentation.
Sinus core specimens were obtained from 24 subjects and analyzed for percentage of new bone, grafting material, fibrous connective tissue and marrow. Investigators found vital bone formation was significantly greater in the four to five month specimens filled with ABBM and rhPDGF (21.1%) compared to ABBM alone (11.8%). These results indicate more rapid formation of vital bone with addition of rhPDGF may allow for earlier implant placement. The authors suggest additional clinical studies to further refine the optimal time course for rhPDGF treatment.
About the Bluestone Center for Clinical Research: The Bluestone Center for Clinical Research, in conjunction with the NYU Oral Cancer Center, is an academic research organization located at the NYU College of Dentistry. Bluestone’s mission is to take a creative scientific approach to transform world health. Bluestone is dedicated to conducting research in oral cancer, cancer symptomology, pharmaceuticals, medical devices, emerging biotechnology, periodontics, implants, and oral health products.
--New York University College of Dentistry (NYUCD) is the third oldest and the largest dental school in the US, educating more than 8 percent of all dentists. NYUCD has a significant global reach and provides a level of national and international diversity among its students that is unmatched by any other dental school.